Canopy Growth's First Quarter of Broad-Based Growth: A Turning Point or a Calm Before the Storm?
Fiscal 2027 kicks off with revenue up 13%, margins up 600bps, and a clear path to positive adjusted EBITDA.
WEED.TO · Earnings Call · 2026-08-07
A Turning Point at Canopy
Canopy Growth has spent the past year under CEO Luc Mongeau "fixing the foundations," and the first quarter of fiscal 2027 suggests the repair work is finally showing up in the numbers. The company reported net revenue of CAD 81.2 million, up 13% year-over-year, with growth across every business line — a first since Mongeau took the helm. “Fiscal 2027 is off to a strong start, and it's built on real momentum from fiscal 2026.” — Luc Mongeau, Chief Executive Officer · 2026-08-07 The cannabis segment grew 14%, while Storz & Bickel returned to growth, up 6%. More importantly, adjusted gross margin expanded by 600 basis points to 31%, and the adjusted EBITDA loss narrowed by 59% to CAD 3.2 million.Cultivation and International Expansion
The strategic acquisition of MTL Cannabis is proving to be the catalyst for a step-change in the company's core horticulture. Mongeau emphasized that "cultivation efficiency" is now a company-wide priority, with master growers from MTL leading improvements in yield, THC levels, and cost per gram. “We should really start seeing impact at the end of Q2, beginning of Q3, when we start gradually realizing the benefits of improved yield and improved quality.” — Luc Mongeau, Chief Executive Officer · 2026-08-07 These gains are expected to be a key driver of near-term margin expansion and will also fuel the international business. The international market remains a major growth vector, with Poland now a top-three supplier and the U.K. expected to begin receiving flower shipments in the second half of the fiscal year. The company is pursuing EU GMP certification for its Smiths Falls facility, which would make Canopy one of the only domestic companies with end-to-end EU GMP cultivation, manufacturing, and finished product processing. As Mongeau put it, "We take cannabis extremely seriously. We've got the internal capabilities to really build integrity, reliability, and trust in the supply chain." This certification, combined with a robust European distribution network, positions the company to capitalize on what is expected to be a tightening regulatory environment.Margins, Costs, and the Path to Profitability
The margin story is not just about cultivation. The MTL integration is already yielding synergies — management is actively executing against CAD 8 million of the CAD 10 million target, with the potential to exceed it. CFO Tom Stewart noted, “In the near term, we're targeting to get up to the mid-30s, hopefully on the higher end as we're exiting this year.” — Tom Stewart, Chief Financial Officer · 2026-08-07 That would build on the 31% adjusted gross margin reported in Q1. Storz & Bickel, which posted a 48% gross margin in the quarter, is also contributing meaningfully to the mix. Despite the solid quarter, management remains acutely aware of the headwinds, most notably the reduced reimbursement rates from Veterans Affairs Canada. The company has been working to mitigate the impact by integrating customer care, renegotiating supplier pricing, and expanding patient-focused product formats. Tom Stewart acknowledged, “We weathered that storm better than probably some of our competitors in the quarter.” — Tom Stewart, Chief Financial Officer · 2026-08-07 The reimbursement changes have forced a reset in the medical business, but management insists the growth drivers — patient count and order volume — remain strong. The broader strategic narrative is one of discipline and focus. As Mongeau stated in his closing remarks,That vision is a far cry from the company's history of overexpansion and inconsistent execution. The shift under Mongeau has been from "large corporation" to "fighting business units," a theme echoed in prior calls. On the Q3 FY2026 call, he described the improvements in supply: “We're in a good place where we can really meet the demand better than we did in the past.” — Luc Mongeau, Chief Executive Officer · 2026-02-06 And on the Q2 FY2026 call, Tom Stewart emphasized the relentless focus on EBITDA: “We'll keep pushing as much as we can here.” — Thomas Stewart, Chief Financial Officer · 2025-11-07 The market has yet to reward the stock — it trades at a market cap of roughly CAD 642 million, a fraction of its former glory. But the positive adjusted EBITDA target for fiscal 2027 is now in sight, and the margins are moving in the right direction. The question is whether the cultivation gains and the EU GMP certification can be delivered on schedule, and whether the U.S. opportunity — where Canopy holds stakes in Acreage, Wana, and Jetty — can be unlocked without diluting the focus on Canada and Europe. For now, the first quarter of fiscal 2027 is a genuine sign that the turnaround is real.Building a global, consumer-centric company with a clear and uncompromising ambition to lead the world in bettering lives through cannabis. That's the company behind the results we've just shared with us, and it's the company you'll see reflected in our new identity.